Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT00544219
First received: October 13, 2007
Last updated: June 14, 2016
Last verified: June 2016